May 19, 2020
NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment
Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement